Title: Targeting angiogenesis for cancer and intraocular vascular disorders: lessons learned and future perspectives

Speaker: Dr. Napoleone Ferrara (拿破仑·费拉拉, 美国科学院院士)

Host: Dr. Xuri Li

Date: 10:00 – 11:00, November 14, 2018

Venue: Academic Hall, 2F, Science Building, Zhongshan Ophthamic Center (Zhujiang New Town Campus)

      广州金穗路7号，中山大学中山眼科中心珠江新城院区，科技楼二楼学术报告厅

Dr. Napoleone Ferrara, University of California, USA

Dr. Ferrara earned his M.D. degree in 1981 from the University of Catania Medical School in Italy. After completing his postdoctoral research at the University of California, San Francisco, he joined Genentech Inc. in 1988, where he spent nearly 25 years discovering and then working on the molecular characterization and therapeutic applications of VEGF-A, which resulted in the development of bevacizumab, the first anti-angiogenic agent to be approved by the FDA for cancer therapy. His research also led to the development of ranibizumab, which has been approved by FDA for the treatment of multiple intraocular neovascular disorders. In 2013, Dr. Ferrara joined the University of California, San Diego as a Distinguished Professor of Pathology, Distinguished Adjunct Professor of Ophthalmology and Senior Deputy Director for Basic Sciences of the Moores Cancer Center.

Dr. Ferrara has authored over 300 scientific publications. He is also the recipient of numerous awards including the Lasker-deBakey Clinical Medical Research Award, the Breakthrough Prize in Life Sciences, the Champalimaud Vision Award and the Gairdner Foundation International Award. Dr. Ferrara is a member of the National Academy of Sciences, USA.

                              Zhongshan Ophthalmic Center, Sun Yat-Sen University

State Key Laboratory of Ophthalmology